X. G. Muro

发表

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

S. Culine, J. Hainsworth, R. Huddart, 2017, The Lancet.

Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC)

E. Gallardo, J. Maroto, B. Mellado, 2013, Clinical and Translational Oncology.

Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations

M. Climent, L. Paz-Ares, E. Esteban, 2010, Cancer and Metastasis Reviews.

Randomized phase II study of maintenance vinflunine versus best supportive care after first line chemotherapy in patients with advanced urothelial carcinoma : The MAJA study ( SOGUG 2011 / 02 )

Begoña, E. Gallardo, J. Bellmunt, 2017 .

Phase II study of gemcitabine (GEM) plus sirolimus (SIR) in previously treated patients with advanced soft tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.

N. Mulet-Margalef, J. López-Martín, J. Broto, 2014 .

Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib

J. Blay, A. Italiano, A. Le Cesne, 2022, Cancers.

Postchemotherapy resections of residual masses from metastatic nonseminomatous testicular germ cell tumors. A Spanish Germ Cell Group study

L. Paz-Ares, J. Aparicio, E. Alba, 2005 .

Cancer Therapy : Preclinical Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors

G. Capellá, A. Villanueva, E. Condom, 2009 .

Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and resistant human testicular germ cell tumors Running title: Effect of sunitinib in orthotopic testicular GCT

A. Villanueva, A. Vidal, X. G. Muro, 2008 .

Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study

E. Brendel, O. Gallego, J. Broto, 2014, Investigational New Drugs.

Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma

M. Climent, L. Paz-Ares, E. Esteban, 2010, Cancer and Metastasis Reviews.

Nilotinib, imatinib, and GIST therapy.

X. G. Muro, 2015 .

IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

M. Galsky, E. Kikuchi, I. Davis, 2019, Annals of Oncology.

Phase II trial of gemcitabine plus rapamycin as second line in advanced osteosarcoma: A Spanish Group for Sarcoma Research (GEIS) Study.

J. Mora, C. Valverde, J. Broto, 2015 .

Multi-institutional European single-arm phase II trial of pazopanib in advanced malignant/dedifferentiated solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study.

J. Blay, E. Álava, A. Italiano, 2017 .

A single arm, multicenter, open-label phase II study of orally administered GW572016 as single-agent, second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract. Interim analysis. : Abstract #4615

J. Machiels, D. Richel, M. Grimm, 2004 .

Primary intracranial spindle cell sarcoma with RMS-like features share a highly distinct methylation profile and DICER1 mutations

David T. W. Jones, Dominik, Mora, 2022 .

Redefining the IGCCCG classification in advanced non-seminoma

L. Collette, R. Huddart, D. Feldman, 2019, Annals of Oncology.

Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.

O. Etxaniz, A. Medina, S. Villà, 2021 .

Phase II randomized study of first line avelumab with carboplatin-gemcitabine versus carboplatin-gemcitabine alone in patients with metastatic urothelial carcinoma ineligible for cisplatin-based therapy.

M. Climent, B. Mellado, J. Bellmunt, 2018 .

New advances in genitourinary cancer: evidence gathered in 2014

M. Climent, E. Gallardo, B. Mellado, 2015, Cancer and Metastasis Reviews.

European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG).

W. Siegert, S. Fosså, S. Culine, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG).

M. Climent, L. Paz-Ares, J. Aparicio, 2002, European urology.

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.

Robin L. Jones, W. Read, H. Tawbi, 2017, The Lancet. Oncology.

Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population

X. G. Del Muro, J. Pérez-Gracia, D. Castellano, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA46PHASE 2 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DOVITINIB IN PATIENTS (PTS) WITH GASTROINTESTINAL STROMAL TUMOR (GIST) REFRACTORY AND/OR INTOLERANT TO IMATINIB (IM)

J. Blay, B. Bui, A. Cesne, 2014 .

Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study.

M. Galsky, S. Park, E. Kikuchi, 2021 .

Abstract CT042: Atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Updated overall survival (OS) from the randomized phase III study IMvigor130

M. Galsky, S. Park, P. O’Donnell, 2021, Clinical Trials.

Prognostic factors in advanced seminoma: An analysis from the IGCCCG Update Consortium.

L. Collette, R. Huddart, D. Feldman, 2020 .

884 Long-term results following one course of adjuvant chemotherapy for high-risk stage I non-seminomatous germ cell tumors: the Spanish germ cell cancer group experience

A. Barnadas, P. Maroto, J. Terrasa, 2003 .

Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.

J. Nolla, R. Palmero, E. Domingo-Domènech, 2018, Autoimmunity reviews.

DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature.

Juan F. García, N. Malats, F. Real, 2020 .

GEIS-21: A multicentric phase II study of intensive chemotherapy including gemcitabine/docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish Group of Sarcoma Investigation (GEIS).

J. Mora, E. Álava, C. Valverde, 2016 .

Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy

D. Spaeth, G. Tonini, X. G. Del Muro, 2016, BMC Cancer.

Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer.

X. Castellsagué, E. Condom, F. Vigués, 2000, European journal of cancer.

Abstract CT040: Updated overall survival (OS) analysis of atezolizumab (atezo) monotherapy vs chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (mUC) in IMvigor130

M. Galsky, S. Park, M. Santis, 2021, Clinical Trials.

Small Cell Carcinoma of the Urinary Bladder

Ximing J. Yang, Haiqun Lin, F. Algaba, 2000, European Urology.

Robin L. Jones, W. Read, H. Tawbi, 2017, The Lancet. Oncology.

698O Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

M. Galsky, E. Kikuchi, I. Davis, 2020 .

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).

J. Carles, M. Margelí, J. Aparicio, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Preliminary data of nilotinib in the first-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST).

J. Blay, H. Joensuu, P. Casali, 2010 .

Phase I study of pazopanib in combination with interferon alfa in patients with advanced renal cell carcinoma (RCC) and other primary tumors: A Spanish Oncology Genitourinary Group (SOGUG) study.

J. García-Donas, I. Durán, M. Gil-Martin, 2014 .

ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor

A. Pandiella, A. Villanueva, E. Condom, 2013, International Journal of Cancer.